AUROPHARMA — Aurobindo Pharma Share Price
0.000.00%
Last trade - 00:00- IN₹691.91bn
- IN₹689.50bn
- IN₹317.24bn
- 89
- 35
- 39
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.47 | ||
| PEG Ratio (f) | 1.22 | ||
| EPS Growth (f) | 15.61% | ||
| Dividend Yield (f) | 0.48% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.12 | ||
| Price to Tang. Book | 2.44 | ||
| Price to Free Cashflow | 49.22 | ||
| Price to Sales | 2.18 | ||
| EV to EBITDA | 10.44 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.12% | ||
| Return on Equity | 11.16% | ||
| Operating Margin | 15.62% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 247,746.2 | 234,554.9 | 248,553.8 | 290,018.7 | 317,237.3 | 342,914.01 | 369,741.71 | 6.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +17.28 | -18.07 | -30.38 | +72.57 | +4.93 | +17.54 | +11.01 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its Key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. The Company is marketing its products globally in approximately 150 countries. The Company's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltda, and others.
Directors
- K Ragunathan NEC (58)
- K. Nityananda Reddy VCH (63)
- Santhanam Subramanian CFO
- B. Adi Reddy CCO
- M. Madan Reddy EDR (60)
- P. Sarath Reddy EDR (36)
- M. Sivakumaran EDR (78)
- P.V. Reddy NED (63)
- Savita Mahajan NID
- Avnit Singh NID (57)
- Girish Vanvari NID
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- December 26th, 1986
- Public Since
- January 19th, 1995
- No. of Employees
- 8,797
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 580,801,623
- Address
- Water Mark Building,, Plot No. 11, HYDERABAD, 500032
- Web
- https://www.aurobindo.com/
- Phone
- +91 4066725000
- Auditors
- Deloitte Haskins & Sells
Upcoming Events for AUROPHARMA
Q2 2026 Aurobindo Pharma Ltd Earnings Release
Similar to AUROPHARMA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Aurobindo Pharma share price?
As of Today at 19:25 UTC, shares in Aurobindo Pharma are trading at IN₹1,191.30. This share price information is delayed by 15 minutes.
How has the Aurobindo Pharma share price performed this year?
Shares in Aurobindo Pharma last closed at IN₹1,191.30 and the price had moved by -5.05% over the past 365 days. In terms of relative price strength the Aurobindo Pharma share price has underperformed the S&P BSE 100 Index by -8.43% over the past year.
What are the analyst and broker recommendations for Aurobindo Pharma?
The overall consensus recommendation for Aurobindo Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aurobindo Pharma dividend yield?
Aurobindo Pharma does not currently pay a dividend.
Does Aurobindo Pharma pay a dividend?
Aurobindo Pharma does not currently pay a dividend.
When does Aurobindo Pharma next pay dividends?
Aurobindo Pharma does not currently pay a dividend.
How do I buy Aurobindo Pharma shares?
To buy shares in Aurobindo Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aurobindo Pharma?
As of the previous close price of IN₹1,191.30, shares in Aurobindo Pharma had a market capitalisation of IN₹691.91bn.
Where are Aurobindo Pharma shares listed?
Here are the trading details for Aurobindo Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: AUROPHARMA
What kind of share is Aurobindo Pharma?
Based on an overall assessment of its quality, value and momentum Aurobindo Pharma is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aurobindo Pharma share price forecast for 2025?
The analyst consensus target price for shares in Aurobindo Pharma is IN₹1,393.46. That is 16.97% above the last closing price of IN₹1,191.30.
Analysts covering Aurobindo Pharma currently have a consensus Earnings Per Share (EPS) forecast of IN₹70.30 for the next financial year.
Find out moreWhat is the trend in the Aurobindo Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aurobindo Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -15.5%.
As of the last closing price of IN₹1,191.30, shares in Aurobindo Pharma were trading -3.71% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aurobindo Pharma PE Ratio?
The Aurobindo Pharma PE ratio based on its reported earnings over the past 12 months is 16.47. The shares last closed at IN₹1,191.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aurobindo Pharma?
Aurobindo Pharma's management team is headed by:
- K Ragunathan - NEC
- K. Nityananda Reddy - VCH
- Santhanam Subramanian - CFO
- B. Adi Reddy - CCO
- M. Madan Reddy - EDR
- P. Sarath Reddy - EDR
- M. Sivakumaran - EDR
- P.V. Reddy - NED
- Savita Mahajan - NID
- Avnit Singh - NID
- Girish Vanvari - NID